Browse studies

Find your next paid study

24 recruiting studies matching your filters

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) loc…

Cancer Harboring BRAF AlterationsHGGLGG+1 more

Estimated

~$10 – $8,750

Fore BiotherapeuticsNCT05503797

Observational

Neural and Metabolic Factors in Carbohydrate Reward: An Examination of Speed

Dietary factors contributed to nearly 50% of all cardiometabolic deaths in the US in 2012, making it one of the leading causes of preventable death in the US, …

Carbohydrate Metabolism

Estimated

~$10 – $6,250

Virginia Polytechnic Institute and State UniversityNCT06053294

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.

Prospective Observational StudyGemcitabineDocetaxel+5 more

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07662018

Phase 1

A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorub…

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more

Estimated

~$10 – $7,500

AIDS Malignancy ConsortiumNCT04139304

Phase 2

A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

OTC DeficiencyOrnithine Transcarbamylase DeficiencyOTCD

Estimated

~$10 – $8,750

Arcturus Therapeutics, Inc.NCT06488313

Phase 2

A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Cell Lymphoma

This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednis…

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer Center

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization per…

Antimicrobial Drug ResistanceAntibiotic Resistant InfectionClostridium Difficile+5 more

Estimated

~$10 – $750

The Methodist Hospital Research InstituteNCT06258551

Congenital Muscle Disease Patient and Proxy Reported Outcome Study

The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse…

Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) DeficiencyAlpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)+49 more

Hepatic Histopathology in Urea Cycle Disorders

This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any…

Urea Cycle DisorderOrnithine Transcarbamylase DeficiencyCitrullinemia 1+7 more

Estimated

~$10 – $750

Baylor College of MedicineNCT04908319

Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, …

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+340 more

Phase 1

Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers

Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effec…

ImageWarburg EffectTumors

Estimated

~$10 – $6,250

University of Maryland, BaltimoreNCT05697406

Phase 1

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability,…

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

Estimated

~$10 – $8,750

Avistone Biotechnology Co., Ltd.NCT06716138